Webinar Date and Time: Tuesday, November 8, 2022 4:30 – 5:30 PM EST
The COVID-19 pandemic has brought many challenges to lymphoma patients and caregivers. Compared to the general population, individuals living with lymphoma are at a greater risk of developing severe COVID outcomes if infected. This risk can raise concern about vaccination, response to cancer treatment, and ways to remain healthy. In this presentation, Dr. Nathalie Johnson will be providing an update on the COVID-19 pandemic and vaccines as it pertains to lymphoma and CLL patients. This talk will help one understand how the immune system responds to viral infections and COVID-19, and how this response differs in those diagnosed with lymphoma. The most relevant information will be provided on treatment options for COVID-19 and prevention measures if you or someone you know has lymphoma.
Speaker: Dr. Nathalie Johnson
Dr. Nathalie Johnson is an associate professor in the departments of Medicine and Oncology at McGill University. She performs translational and clinical research at the Jewish General Hospital (JGH) since 2010. She established a lymphoma tumor bank that she shares with other investigators to advance biomedical research in Quebec and Canada. Her translational research focuses on identifying mechanisms of therapeutic resistance to conventional and novel therapies, including immunotherapy. This is funded by numerous agencies including CCSRI and CIHR. She is also the primary investigator of several clinical trials that test novel therapies in patients with newly diagnosed or relapsed lymphoma. She has been the program director of the Clinical Investigator Program at McGill University since 2018.